165 related articles for article (PubMed ID: 23927471)
21. Effects of the nitric oxide donor JS-K on the blood-tumor barrier and on orthotopic U87 rat gliomas assessed by MRI.
Weidensteiner C; Reichardt W; Shami PJ; Saavedra JE; Keefer LK; Baumer B; Werres A; Jasinski R; Osterberg N; Weyerbrock A
Nitric Oxide; 2013 Apr; 30():17-25. PubMed ID: 23370169
[TBL] [Abstract][Full Text] [Related]
22. Nitroreductase-activated nitric oxide (NO) prodrugs.
Sharma K; Sengupta K; Chakrapani H
Bioorg Med Chem Lett; 2013 Nov; 23(21):5964-7. PubMed ID: 24050886
[TBL] [Abstract][Full Text] [Related]
23. Sphingosine 1-Phosphate Liposomes for Targeted Nitric Oxide Delivery to Mediate Anticancer Effects against Brain Glioma Tumors.
Liu Y; Wang X; Li J; Tang J; Li B; Zhang Y; Gu N; Yang F
Adv Mater; 2021 Jul; 33(30):e2101701. PubMed ID: 34106489
[TBL] [Abstract][Full Text] [Related]
24. JS-K, a glutathione/glutathione S-transferase-activated nitric oxide releasing prodrug inhibits androgen receptor and WNT-signaling in prostate cancer cells.
Laschak M; Spindler KD; Schrader AJ; Hessenauer A; Streicher W; Schrader M; Cronauer MV
BMC Cancer; 2012 Mar; 12():130. PubMed ID: 22462810
[TBL] [Abstract][Full Text] [Related]
25. JS-K, a nitric oxide prodrug, induces DNA damage and apoptosis in HBV-positive hepatocellular carcinoma HepG2.2.15 cell.
Liu Z; Li G; Gou Y; Xiao D; Luo G; Saavedra JE; Liu J; Wang H
Biomed Pharmacother; 2017 Aug; 92():989-997. PubMed ID: 28605880
[TBL] [Abstract][Full Text] [Related]
26. A reactive oxygen species activation mechanism contributes to JS-K-induced apoptosis in human bladder cancer cells.
Qiu M; Chen L; Tan G; Ke L; Zhang S; Chen H; Liu J
Sci Rep; 2015 Oct; 5():15104. PubMed ID: 26458509
[TBL] [Abstract][Full Text] [Related]
27. Cyclooxygenase (COX) Inhibition by Acetyl Salicylic Acid (ASA) Enhances Antitumor Effects of Nitric Oxide in Glioblastoma In Vitro.
Guenzle J; Garrelfs NWC; Goeldner JM; Weyerbrock A
Mol Neurobiol; 2019 Sep; 56(9):6046-6055. PubMed ID: 30715649
[TBL] [Abstract][Full Text] [Related]
28. Permeability changes in response to NONOate and NONOate prodrug derived nitric oxide in a blood-brain barrier model formed by primary porcine endothelial cells.
Winter S; Konter J; Scheler S; Lehmann J; Fahr A
Nitric Oxide; 2008 May; 18(3):229-39. PubMed ID: 18284923
[TBL] [Abstract][Full Text] [Related]
29. Activation of the c-Jun N-terminal kinase/activating transcription factor 3 (ATF3) pathway characterizes effective arylated diazeniumdiolate-based nitric oxide-releasing anticancer prodrugs.
Maciag AE; Nandurdikar RS; Hong SY; Chakrapani H; Diwan B; Morris NL; Shami PJ; Shiao YH; Anderson LM; Keefer LK; Saavedra JE
J Med Chem; 2011 Nov; 54(22):7751-8. PubMed ID: 22003962
[TBL] [Abstract][Full Text] [Related]
30. Diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of 5-(4-carboxymethylphenyl)-1-(4-methanesulfonylphenyl)-3-trifluoromethyl-1H-pyrazole and its aminosulfonyl analog: Synthesis, biological evaluation and nitric oxide release studies.
Abdellatif KR; Chowdhury MA; Dong Y; Das D; Yu G; Velázquez C; Suresh MR; Knaus EE
Bioorg Med Chem; 2009 Jul; 17(14):5182-8. PubMed ID: 19500994
[TBL] [Abstract][Full Text] [Related]
31. Gene expression profiling for nitric oxide prodrug JS-K to kill HL-60 myeloid leukemia cells.
Liu J; Malavya S; Wang X; Saavedra JE; Keefer LK; Tokar E; Qu W; Waalkes MP; Shami PJ
Genomics; 2009 Jul; 94(1):32-8. PubMed ID: 19348908
[TBL] [Abstract][Full Text] [Related]
32. JS-K, a glutathione S-transferase-activated nitric oxide donor with antineoplastic activity in malignant gliomas.
Weyerbrock A; Osterberg N; Psarras N; Baumer B; Kogias E; Werres A; Bette S; Saavedra JE; Keefer LK; Papazoglou A
Neurosurgery; 2012 Feb; 70(2):497-510; discussion 510. PubMed ID: 21849924
[TBL] [Abstract][Full Text] [Related]
33. JS-K, a nitric oxide pro-drug, regulates growth and apoptosis through the ubiquitin-proteasome pathway in prostate cancer cells.
Tan G; Qiu M; Chen L; Zhang S; Ke L; Liu J
BMC Cancer; 2017 May; 17(1):376. PubMed ID: 28549433
[TBL] [Abstract][Full Text] [Related]
34. JS-K, a nitric oxide-releasing prodrug, induces breast cancer cell death while sparing normal mammary epithelial cells.
McMurtry V; Saavedra JE; Nieves-Alicea R; Simeone AM; Keefer LK; Tari AM
Int J Oncol; 2011 Apr; 38(4):963-71. PubMed ID: 21271218
[TBL] [Abstract][Full Text] [Related]
35. Aryl bis(diazeniumdiolates): potent inducers of S-glutathionylation of cellular proteins and their in vitro antiproliferative activities.
Andrei D; Maciag AE; Chakrapani H; Citro ML; Keefer LK; Saavedra JE
J Med Chem; 2008 Dec; 51(24):7944-52. PubMed ID: 19053760
[TBL] [Abstract][Full Text] [Related]
36. Effects of JS-K, a novel anti-cancer nitric oxide prodrug, on gene expression in human hepatoma Hep3B cells.
Dong R; Wang X; Wang H; Liu Z; Liu J; Saavedra JE
Biomed Pharmacother; 2017 Apr; 88():367-373. PubMed ID: 28122301
[TBL] [Abstract][Full Text] [Related]
37. Hantzsch 1,4-dihydropyridines containing a diazen-1-ium-1,2-diolate nitric oxide donor moiety to study calcium channel antagonist structure-activity relationships and nitric oxide release.
Nguyen JT; Velázquez CA; Knaus EE
Bioorg Med Chem; 2005 Mar; 13(5):1725-38. PubMed ID: 15698790
[TBL] [Abstract][Full Text] [Related]
38. Novel nonsteroidal antiinflammatory drugs possessing a nitric oxide donor diazen-1-ium-1,2-diolate moiety: design, synthesis, biological evaluation, and nitric oxide release studies.
Velázquez C; Praveen Rao PN; Knaus EE
J Med Chem; 2005 Jun; 48(12):4061-7. PubMed ID: 15943479
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and biological evaluation of 1,4-dihydropyridine calcium channel modulators having a diazen-1-ium-1,2-diolate nitric oxide donor moiety for the potential treatment of congestive heart failure.
Velázquez C; Knaus EE
Bioorg Med Chem; 2004 Jul; 12(14):3831-40. PubMed ID: 15210150
[TBL] [Abstract][Full Text] [Related]
40. JS-K, a GST-activated nitric oxide donor prodrug, enhances chemo-sensitivity in renal carcinoma cells and prevents cardiac myocytes toxicity induced by Doxorubicin.
Qiu M; Ke L; Zhang S; Zeng X; Fang Z; Liu J
Cancer Chemother Pharmacol; 2017 Aug; 80(2):275-286. PubMed ID: 28608259
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
